Investigators at The Feinstein Institute for Medical Research discovered dozens of new genetic variations associated with a person’s general cognitive ability. The findings, which were published online today in Cell Reports, have the potential to help researchers develop more targeted treatment for cognitive and memory disorders.
Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.
AbbVie (ABBV), a global biopharmaceutical company, and Alector, a privately owned biotechnology company, announced a global strategic collaboration to develop and commercialize medicines to treat Alzheimer's disease and other neurodegenerative disorders.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.